# Efficacy and Safety Evaluation of the Intralesional Recombinant Human Epidermal Growth Factor (rhEGF) in Subjects With Diabetic Foot Ulcer.

> **NCT02554851** · PHASE3 · UNKNOWN · sponsor: **The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz)** · enrollment: 304 (actual)

## Conditions studied

- Foot Ulcer, Diabetic
- Epidermal Growth Factor

## Interventions

- **DRUG:** recombinant human Epidermal Growth Factor (rhEGF)
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT02554851
- **Lead sponsor:** The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz)
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-01
- **Primary completion:** 2019-12
- **Final completion:** 2023-12
- **Target enrollment:** 304 (ACTUAL)
- **Last updated:** 2023-06-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02554851

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02554851, "Efficacy and Safety Evaluation of the Intralesional Recombinant Human Epidermal Growth Factor (rhEGF) in Subjects With Diabetic Foot Ulcer.". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02554851. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*